Endogenous bystander killing mechanisms enhance the activity of novel FAP-specific CAR-T cells against glioblastoma.
Wenbo YuNga Th TruongRuhi PolaraTessa GargettMelinda N TeaStuart M PitsonMichaelia P CockshellClaudine S BonderLisa M EbertMichael P BrownPublished in: Clinical & translational immunology (2024)
Our findings advance FAP as a leading candidate for clinical CAR-T therapy of glioblastoma and highlight under-recognised antigen nonspecific mechanisms that may contribute meaningfully to the antitumor activity of CAR-T cells.
Keyphrases